PHASE-II EVALUATION OF SINGLE-AGENT CARBOPLATIN IN ADVANCED THYROID-CARCINOMA
- Authors:
- Published online on: November 1, 1994 https://doi.org/10.3892/or.1.6.1217
- Pages: 1217-1218
Metrics: Total
Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )
Abstract
Single agent carboplatin was used in a phase II trial to treat patients with metastatic thyroid cancer who had failed surgery, radiation therapy, or radioactive iodine. Carboplatin was administered at a dose of 400 mg/m(2) every 28 days on an outpatient basis. Eight patients with a variety of tumor histologies were enrolled. No patient had a response to treatment and the average time to disease progression while on treatment was 5.4 months. Toxicity was mild and included hearing loss in one patient. There have been few studies using newer agents in patients with metastatic thyroid cancer who failed surgery and radioactive iodine. These results underline the need for larger intergroup trials with newer agents.
